Afinitor everolimus regulatory update

The U.K.'s NICE issued a second final appraisal determination (FAD) recommending against use of Afinitor everolimus from Novartis for second-line treatment of advanced renal cell carcinoma (RCC), despite a revised patient access scheme submitted by the company. Novartis submitted the undisclosed revision after a July FAD in which the committee said Afinitor does not provide enough benefit to patients to justify its cost (see BioCentury, July 5). ...